CN113975303A - Application of Cordyceps guangdongensis in preparation of product for preventing or treating intestinal dysbacteriosis or its related diseases - Google Patents

Abstract

The invention discloses an application of Guangdong cordyceps in preparing a product for preventing or treating intestinal flora imbalance or related diseases thereof, belonging to the field of intestinal flora regulating medicines. The inventor researches and discovers that the cordyceps guangdongensis can not only obviously contribute to diversification and structural improvement of intestinal flora, but also show obvious prevention or treatment effects on diseases related to the intestinal flora structure, for example, the cordyceps guangdongensis can effectively improve intestinal flora imbalance caused by chronic renal failure, and after the cordyceps guangdongensis sporophore powder is perfused for a period of time, the abundance of intestinal flora of normal mice and mice with chronic renal failure in phyla class, a class, an order, a family, a genus and a species level is changed, so that the cordyceps guangdongensis sporophore not only can adjust the intestinal flora structure of the mice in a normal state, but also has an obvious adjusting effect on the intestinal flora of the mice in a disease state, can be used for preparing medicines for adjusting the intestinal flora of the chronic renal failure, and can also be used for preparing foods or health-care products for adjusting the intestinal flora.

Description

Application of Cordyceps guangdongensis in preparation of product for preventing or treating intestinal dysbacteriosis or its related diseases

Technical Field

The invention relates to the field of intestinal flora regulating medicines, in particular to application of cordyceps guangdongensis in preparing food, health-care products or medicines for preventing or treating intestinal flora imbalance or related diseases thereof.

Background

With the gradual change of people's eating habits and the influence of environmental pollution, the incidence of various chronic diseases is remarkably increased in recent years. In these chronic diseases, however, disturbances and deregulation of the intestinal flora are associated in many cases. Normally, the intestinal flora is in a dynamic balance and is in a symbiotic state with the body. The intestinal flora not only participates in the physiological processes of digestion and absorption of nutrient substances, energy metabolism and the like of organisms, but also participates in immune reaction, host defense, biological barriers and the like of the organisms, and has important influence on various physiological functions of the organisms. Once the intestinal flora is disordered in structure and function, dysfunction of each system of the body can be caused, and diseases can be caused.

Changes in gut microbiota are closely related to a variety of diseases including kidney disease, obesity, diabetes, cardiovascular disease, hypertension, depression, aging of the body, multiple sclerosis, Amyotrophic Lateral Sclerosis (ALS), and the like. If the constitution of intestinal flora of obese people is different from that of normal people, the abundance and diversity of intestinal microorganisms are reduced, the number of firmicutes is relatively increased, the bacteroidetes is reduced, and the ratio of the number of bacteroides to the number of firmicutes is reduced; the intestinal tract of the patient with atherosclerosis is rich in corilaginella; the bacteroidetes in intestinal flora of patients with rheumatoid Arthritis (AR) is reduced, and the prevotella, actinomycetemcomitans and corinella are increased; studies on degenerative neurological diseases such as Parkinson's Disease (PD) have shown that butyrate bacteria such as ralstonia, coprococcus and ross, which have anti-inflammatory effects, are significantly reduced in the stools of PD patients, with a corresponding increase in proteobacteria and the like associated with pro-inflammatory effects. It follows that modulation of the intestinal flora plays a very important role in the treatment of various diseases.

Kidney disease is a group of diseases that seriously endanger human health. The incidence of kidney disease has been on the rise in recent years. Chronic renal failure is a clinical syndrome appearing in the later stage of chronic kidney disease patients, after the renal function of the patients fails, a plurality of wastes generated by the metabolism of organisms cannot be discharged out of the body through the kidney and gradually accumulate, and enter the intestinal cavity through the intestinal wall blood vessel, so that uremic toxoid enters the intestinal tract, the environment on which the intestinal flora lives is promoted to change, and the structure, the composition, the distribution, the quantity and the like of the intestinal flora are influenced to obviously change. One of the high risk factors for the progression of chronic renal failure to uremia is a disturbance of the intestinal flora, which is mainly characterized by an increase in the number of opportunistic pathogens that produce uremic toxins and a decrease in the number of probiotics. One of the current methods for treating disease pairs of chronic renal failure is to restore gut flora balance using microbial agents. Research shows that some traditional Chinese medicine microecological regulators such as purslane polysaccharide, uremia clearing granules and the like can effectively regulate the intestinal flora structure of rats with renal failure and improve renal function, thereby achieving the purpose of delaying the development of renal failure diseases.

The cordyceps fungus is a fungus variety with rich nutrition and extremely high medicinal value, and has various remarkable pharmacological activities of resisting tumor, resisting pathogen, resisting oxidation, enhancing immunologic function and the like. At present, more cordyceps sinensis, cordyceps sobolifera, cordyceps militaris and the like which are researched have good effects of protecting the kidney, can reduce the content of blood creatinine and urine creatinine, and can also relieve glomerular injury, improve the kidney function, delay the hardening process of glomeruli and the like.

The Guangdong cordyceps sinensis is an important edible and medicinal cordyceps fungus, has various obvious active effects such as antioxidation, avian influenza virus resistance, aging delay, fatigue resistance, chronic bronchitis improvement, chronic renal failure treatment and the like, and animal experiment results show that the effect of the Guangdong cordyceps sinensis on the intervention of the chronic renal failure is superior to that of an experimental positive control. The research results show that the cordyceps guangdongensis sporocarp can also regulate various intestinal floras, improve the diversity and abundance of the intestinal floras, promote the growth of probiotics, inhibit the growth of harmful bacteria and promote the health of the intestinal tract. In addition, the cordyceps guangdongensis fruiting body can improve the structure and the composition of intestinal flora of mice with chronic renal failure while intervening in the chronic renal failure, and is favorable for improving the symptoms of the chronic renal failure of the mice. Therefore, the cordyceps guangdongensis sporocarp can be used for preparing preparations for preventing and/or treating diseases related to intestinal dysbacteriosis, such as food, health-care products, medicines and the like.

Disclosure of Invention

The invention aims to provide the application of cordyceps guangdongensis in preparing products for preventing or treating intestinal dysbacteriosis or related diseases thereof, including but not limited to foods, health products or medicines; further, the diseases related to the intestinal dysbacteriosis of the present invention include intestinal dysbacteriosis, and various conditions affected by the intestinal dysbacteriosis and various diseases;

preferably, said application is represented by any one of the following aspects:

1) regulating the community composition of the intestinal flora;

2) regulating the diversity of intestinal flora;

3) regulating intestinal flora function;

4) regulating the abundance change of the intestinal flora;

more preferably, the intestinal flora comprises bacteroidetes (bacteriodes), Firmicutes (Firmicutes), Verrucomicrobia (Verrucomicrobia), actinomycetes (Actinobacteria);

more preferably, said intestinal flora comprises the families of the Bacterinaceae (Murebacteriaceae), Prevotella (Prevotella), Lachnospiraceae (Lachnospiraceae), Mycoplasmataceae (Ruminococcaceae);

more preferably, the intestinal flora comprises the genera Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium), Akkermansia (Akkermansia), Rhizoctonia (Clostridium) and Bacteroides (Bacteroides).

The invention also aims to provide the application of the cordyceps guangdongensis in preparing the medicine for treating the chronic renal failure diseases;

preferably, said application is represented by any one of the following aspects:

1) improve the behavior of eating less and drinking more and reduce polyuria;

2) improving the symptoms of listlessness and the like;

3) improving the appearance of the kidney, wherein the appearance of the kidney comprises the color of the kidney, the luster of the appearance, whether the surface of the kidney is rough or withered or not and atrophy;

4) reduce serum creatinine and urea level.

The third purpose of the invention is to provide a medicine for preventing and/or treating diseases related to intestinal dysbacteriosis, which comprises cordyceps guangdongensis sporocarp and a pharmaceutically acceptable carrier.

According to the invention, the sequencing analysis result of intestinal flora shows that the Guangdong cordyceps sinensis sporophore powder for gastric lavage has obvious influence on the intestinal flora structure and abundance of normal mice and chronic renal failure mice.

In the research of a mouse model for interfering with chronic renal failure disease by cordyceps guangdongensis sporophore powder, compared with a blank control group, a mouse in the model group shows the symptoms of eating and drinking less, diuresis, listlessness, lusterless hair color, shedding phenomenon and the like. After the cordyceps guangdongensis sporophore powder is infused into the stomach for 32 days, the symptoms of the model group mice are improved, and the behavior is active, normal diet and drinking water are realized, and the mental state and the fur luster are gradually recovered. The serum biochemical index detection result shows that compared with a blank control group, the serum creatinine and urea of the model group mouse are obviously increased, the serum creatinine and urea of the model group mouse of the intragastric cordyceps sinensis are obviously reduced, and the reduction degree and the intragastric dosage are in a linear relationship. The situation that the Guangdong cordyceps sinensis fruiting body powder for gastric lavage can improve the symptoms of chronic renal failure diseases of mice is shown.

Compared with the prior art, the invention has the beneficial effects that: the invention not only can regulate the intestinal flora to prevent diseases, but also can regulate the intestinal flora of the chronic renal failure mice to be recovered to a normal level, thereby achieving the purpose of treating the imbalance of the intestinal flora and having great economic and social values.

Drawings

FIG. 1 shows principal coordinate (PCoA) analysis of each sample.

FIG. 2 is a difference significance analysis between the white control group CK1 and the Guangdong Cordyceps sinensis group CK2 at the phylum classification level, wherein the contrast is 0.75 g/kg.d.

FIG. 3 is the analysis of the difference significance between the blank control group CK1 and the Guangdong Cordyceps sinensis group CK2 at the classification level.

FIG. 4 is a group classification level difference significance analysis between a blank control group CK1 and a gavage 1.5 g/kg.d Guangdong Cordyceps group CK 3.

FIG. 5 shows the serum creatinine and urea index detection results of each mouse sample after gastric lavage for 32 d.

Fig. 6 is a morphology of the appearance of the kidney of each sample mouse after intragastric administration for 32 d.

FIG. 7 is a group classification level blank control group CK1 and chronic renal failure mouse model group CRF1 group difference significance analysis.

FIG. 8 is a difference significance analysis between CRF1 in a chronic renal failure mouse model group and CRF2 in a Guangdong cordyceps sinensis group with the gavage speed of 0.75 g/kg.d on a classification level.

FIG. 9 is a difference significance analysis between CRF1 in a chronic renal failure mouse model group and CRF3 in a Guangdong cordyceps sinensis group with a gastric lavage amount of 1.5 g/kg.d on a phylum classification level.

FIG. 10 is a bar graph of the colony distribution of intestinal flora at the phylum taxonomic level for each sample mouse.

FIG. 11 is a histogram of the colony distribution of intestinal flora at the genus classification level for each sample mouse.

FIG. 12 is a graph showing the distribution of different bacterial populations in the intestine of each sample mouse.

Detailed Description

The following examples are further illustrative of the present invention and are not intended to be limiting thereof.

The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.

Example 1 Regulation of intestinal flora in Normal mice by Cordyceps guangdongensis fruiting bodies

Preparation of gastric lavage solution of cordyceps guangdongensis sporophore powder

Oven drying Cordyceps guangdongensis fruiting body, pulverizing into powder with ultramicro pulverizer, respectively weighing Cordyceps guangdongensis fruiting body powder 1.875g and Cordyceps guangdongensis fruiting body powder 3.75g, mixing with 50mL physiological saline to obtain Cordyceps guangdongensis solution with concentration of 37.5mg/mL and 75mg/mL, and ultrasonic dissolving for 30 min.

The design basis of the cordyceps guangdongensis fruiting body dose is as follows: the clinical dosage is 0.05 g/kg.d calculated according to the fact that the daily clinical dosage of an adult with the weight of 60kg is 3g of raw materials. The dosage (1.5 g/kg. d) is designed according to 30 times of the clinical dosage of human and is used as the gavage dosage of the cordyceps guangdongensis, the concentration of the gavage sample of the mouse is 0.075g/mL and 0.0375g/mL respectively, and the gavage amount is 0.02 mL/g.d.

The following Guangdong Cordyceps solution is used for intragastric administration.

Second, preparation of experimental mice

50 male C57BL/6J mice without Specific Pathogen (SPF) are selected, the age of the mice is 6 weeks, the weight of the mice is 18 +/-2 g, the mice are bred in cages (10 mice/cage), the temperature of the breeding environment is 21 +/-2 ℃, the relative humidity is 30-70%, the illumination period is 12h, circulation is carried out, and the experimental animals can freely drink water and eat food (enough water and standard nutritional feed are given) during the experimental period. The cage is changed once a week, and the cage can be changed twice a week according to the requirement in special cases. Mice were randomly divided into three groups one week after acclimation, with at least 16 mice per group: a blank control group (gavage normal saline), a 0.75T Guangdong cordyceps sinensis group (the dose of gavage Guangdong cordyceps sinensis sporophore powder is 0.75 g/kg.d), a 1.5T Guangdong cordyceps sinensis group (the dose of the gavage Guangdong cordyceps sinensis sporophore powder is 1.5 g/kg.d), and different groups are subjected to daily gavage of corresponding solutions, and are simultaneously fed with normal drinking water and standard mouse feed for 32 d. The specific gavage amount was adjusted according to the weekly change in mouse body weight during the experiment.

Preparation of mouse fecal sample

Fecal samples from each group of mice were collected 12h after the last gavage. Collecting fresh excrement particles of the mice into a sterile nut tube by adopting a conventional method of grabbing and massaging the abdomen, immediately freezing the fresh excrement particles, and then transferring the fresh excrement particles into a refrigerator at the temperature of 80 ℃ below zero for storage to be tested. At least 0.3g of fecal samples were collected from each mouse, and insufficient samples were collected at one time, and repeated collection was performed at multiple time points on the same day.

Four, 16S rDNA sequencing

After extracting genomic DNA from the Stool sample according to HiPure Stool DNA Kits (Stool DNA extraction kit) instructions, the DNA concentration was detected by a NanoDrop microspectrophotometer, and the DNA purity was detected by agarose gel electrophoresis. The genomic DNA with qualified quality is amplified in the V3+ V4 region of 16s rDNA by using specific primers with barcode. PCR products were purified using AMPure XP Beads, quantified using the ABI StepOneplus Real-Time PCR System (Life Technologies, USA), and sequenced on machine using Hiseq 2500.

Fifthly, data processing and result analysis

Processing raw data: processing sequencing original data by using Trimmomatic and FLASH software (v1.2.7), performing pairing connection according to sequence overlapping bases, splicing paired reads into a sequence when the overlapping length is required to be more than 10bp, and performing quality control filtration on the quality and splicing effect of the reads to obtain an effective sequence.

And (3) identifying the classification status of flora: and (3) performing classification analysis and operable classification unit (OTU) division on the sequences with the similarity lower than 97% by adopting a Usearch software platform, and taking the sequence with the highest abundance in each OTU as a representative sequence of the OTU. The representative sequences of OTUs were compared with template sequences in the Greenenegnes database (Release 13.5) to obtain population information of all OTUs at six classification levels of microorganisms phylum, class, order, family, genus and species.

The analysis results of the principal coordinates (PCoA) show that (figure 1), the blank control group (CK1) and the two Guangdong cordyceps groups (CK2, 0.75T cordyceps group; CK3, 1.5T cordyceps group) can be clearly distinguished, which indicates that the difference among the samples from the three groups is large.

Significance of differences between groups test: as seen from FIG. 2, it was found that gavage of Guangdong Cordyceps sinensis (CK2) at a dose of 0.75 g/kg.d increased the proportion of Bacteroides in the intestinal flora of mice and decreased the proportion of Mycobacteria in the division level of phylum as compared with the blank control group (CK 1). On the genus classification level, it is clear from fig. 3 that cordyceps guangdongensis (CK2) at a dose of 0.75g/kg · d for intragastric administration significantly increased the proportion of the bacteroides group of the family corynebacterium and lactobacillus in the intestinal flora of mice, and decreased the proportion of the bacteroides group of the genus zurich (Turicibacter). As can be seen from FIG. 4, the Guangdong Cordyceps sinensis (CK3) with a dose of 1.5 g/kg.d for intragastric administration can significantly increase the ratio of Lactobacillus flora in intestinal flora of mice.

Example 2 Regulation of Chronic renal failure symptoms in mice by Cordyceps guangdongensis fruiting bodies

First, preparation of experimental mice

Selecting male C57BL/6J mice without Specific Pathogen (SPF), 6 weeks old, 18 +/-2 g weight, cage-separated word breeding (10 mice/cage), wherein the temperature of the breeding environment is 21 +/-2 ℃, the relative humidity is 30-70%, the illumination period is 12h, circulation is carried out, and the experimental period ensures that the experimental animals drink water and eat food freely (enough water and standard nutrient feed are given). The cage is changed once a week, and the cage can be changed twice a week according to the requirement in special cases. As table 1, mice were randomly divided into seven groups one week after acclimation: a blank control group (CK1 group, gavage normal saline), a Guangdong Cordyceps sinensis group 1(CK2, gavage Guangdong Cordyceps sinensis fruiting body powder dosage of 0.75 g/kg. d), a Guangdong Cordyceps sinensis group 2(CK3, gavage Guangdong Cordyceps sinensis fruiting body powder dosage of 1.5 g/kg. d), a model group (CRF1 group, gavage 50mg/kg adenine for 2 weeks + gavage 25mg/kg adenine), guangdong cordyceps group 3(CRF2 group, the dose of the gavage is 25mg/kg adenine and 0.75 g/kg. d of Guangdong cordyceps sporophore powder after the gavage is 50mg/kg adenine for 2 weeks), Guangdong cordyceps group 4(CRF3 group, the dose of the gavage is 25mg/kg adenine and 1.5 g/kg. d of the Guangdong cordyceps sporophore powder after the gavage is 50mg/kg adenine for 2 weeks), and positive control group (CRF4 group, the dose of the gavage is 25mg/kg adenine and 1.5 g/kg. d of uremia-cleared NDQ after the gavage is 50mg/kg adenine for 2 weeks). The different groups were gavaged daily with the corresponding solutions, fed with normal drinking water and standard mouse feed for a total of 32 days. The specific gavage amount was adjusted according to the weekly change in mouse body weight during the experiment.

TABLE 1 Experimental mice grouping and gavage situation table

Second, the influence of Cordyceps guangdongensis with different dosages on the physiological activity state of the mice with chronic renal failure

TABLE 2 Observation table of growth of Cordyceps guangdongensis in chronic renal failure mice

Note: the signs of "+, + + + + + +" and "-" respectively represent the change conditions of three different grades of light, moderate and heavy, and the sign of "-" represents no change.

As can be seen from Table 2, the blank control group (CK1) mice had a normal diet, good mental activity, and normal gross color and defecation after administration for 32 days; the mice in the model group (CRF1) showed the symptoms of poor appetite, polydipsia, listlessness, lusterless hair and shedding phenomenon; and chronic renal failure symptoms of mice in the gavage CRF cordyceps sinensis group (CRF2 and CRF3) and the positive control group (CRF4) are generally improved.

Influence of Cordyceps guangdongensis on serum biochemical indexes of chronic renal failure mice with different doses

After administration for 32 days, compared with a blank control group (CK1), serum creatinine and urea of the mice in the model group (CRF1) are obviously increased, and serum creatinine and urea in the mice in the intragastric CRF cordyceps sinensis group (CRF2 and CRF3) are obviously reduced on average and have a linear relation with the intragastric dose; the serum creatinine and urea levels of mice from gavage CK cordyceps group (CK2, CK3) were not significantly different from CK1 (fig. 5).

Influence of Cordyceps guangdongensis on appearance of kidney of mouse with chronic renal failure

After administration for 32 days, the kidney of the mice of the blank control group (CK1) and the mice of the gavage CK cordyceps group (CK2, CK3) have no difference, are reddish brown and have glossy surfaces; compared with CK1, the mouse kidney tissue morphology of the model group (CRF1) is obviously changed, the mouse kidney color is lighter and slightly whitish, the surface is rough and slightly atrophied, and the mouse kidney has white particles; compared with CRF1, the appearance of kidney tissue of mice in both the intragastric CRF Cordyceps group (CRF2, CRF3) and the positive control group (CRF4) is improved, and the symptoms such as kidney color, atrophy and surface roughness are partially recovered (fig. 6).

Example 3 Effect of Cordyceps guangdongensis fruiting body on intestinal flora of mice with chronic renal failure

First, preparation of experimental mice

Experimental mice were prepared, modeled, grouped, and gavaged with the corresponding solution 32d for use in reference to example 2.

Preparation of mouse fecal sample

Fecal samples from each group of mice were collected 12h after the last gavage. Collecting fresh excrement particles of the mice into a sterile nut tube by adopting a conventional method of grabbing and massaging the abdomen, immediately freezing the fresh excrement particles, and then transferring the fresh excrement particles into a refrigerator at the temperature of 80 ℃ below zero for storage to be tested. At least 0.3g of fecal samples were collected from each mouse, and insufficient samples were collected at one time, and repeated collection at multiple time points on the same day.

Three, 16S rDNA sequencing

After extracting genomic DNA from the Stool sample according to HiPure Stool DNA Kits (Stool DNA extraction kit) instructions, the DNA concentration was detected by a NanoDrop microspectrophotometer, and the DNA purity was detected by agarose gel electrophoresis. The genomic DNA with qualified quality is amplified in the V3+ V4 region of 16s rDNA by using specific primers with barcode. PCR products were purified using AMPure XP Beads, quantified using the ABI StepOneplus Real-Time PCR System (Life Technologies, USA), and sequenced on machine using Hiseq 2500.

Four, processing the original data

Processing sequencing original data by using Trimmomatic and FLASH software (v1.2.7), performing pairing connection according to sequence overlapping bases, splicing paired reads into a sequence when the overlapping length is required to be more than 10bp, and performing quality control filtration on the quality and splicing effect of the reads to obtain an effective sequence.

Fifth, the classification status identification of flora

And (3) performing classification analysis and operable classification unit (OTU) division on the sequences with the similarity lower than 97% by adopting a Usearch software platform, and taking the sequence with the highest abundance in each OTU as a representative sequence of the OTU. The representative sequences of OTUs were compared with template sequences in the Greenenegnes database (Release 13.5) to obtain population information of all OTUs at six classification levels of microorganisms phylum, class, order, family, genus and species.

After the Guangdong Cordyceps sinensis was perfused for 32d, a mouse fecal sample was collected for 16S rDNA sequencing. OTU species classification statistics show that the number of OTU is phyla 11, class 16, order 25, family 53, genus 132, species 226 and OTU 731 respectively.

Six, principal coordinate (PCoA) analysis

As shown in fig. 1, the CRF1 model group was clearly distinguished from the CK1 blank control group and other CRF groups, indicating that the colony structure of the CRF1 model group was clearly different from the CK1 blank control group and other CRF groups.

Seventhly, analysis of significance of difference among groups

As shown in fig. 7, species in which abundance differences exhibited in microbial communities between the placebo group and the CRF model group were compared after 32 days of gavage of cordyceps guangdongensis were mainly of the genus bacillus (rhizobacter) and Bacteroides (Bacteroides) at the genus classification level, and microorganisms of the family corynebacterium (muribacteriaceae) of which the genus was not identified. Compared with the blank control group CK1, the floras of the murine bacillaceae and the Zuricobacter in the CRF1 model group are remarkably reduced, and the floras of the Bacteroides are remarkably increased.

As shown in FIG. 8, the difference in microbiota between the CRF1 model group and the CRF2 Cordyceps group was significant, and at the genus classification level, the species that differed between the two groups were mainly Lactobacillus (Lactobacillus), Ackermania (Akkermansia), Bacteroides (Bacteroides), and non-genus-identified Corynebacteriaceae (Murebacteriaceae). Compared with the CRF1 model group, the CRF2 Cordyceps group mice have significantly reduced intestinal microorganisms of Ackermanella and Bacteroides, and have significantly increased relative abundance of microorganisms of Lactobacillus and Bacteriaceae.

At the phylum level, the species of difference between the CRF1 model group and the CRF3 cordyceps group were mainly bacteroidetes (bacteroides), Verrucomicrobia (Verrucomicrobia) and actinomycetes (Actinobacteria). Compared with the CRF1 model group, the relative abundance of the microorganisms of Bacteroides phylum in intestinal tracts of the mice in the CRF3 cordyceps group is remarkably increased, and the relative abundance of the microorganisms of Microbacteroidetes phylum and Actinomycetes phyla is remarkably reduced (FIG. 9).

Eight, different levels of distribution of each sample flora

At the phylum taxonomic level, as shown in fig. 10, the abundance of gut flora of mice in the blank control group (CK1) was ranked as follows: bacteriodes (bacteroidetes, 43.84%), Firmicutes (Firmicutes, 43.61%), Verrucomicrobia (Verrucomicrobia, 6.98%), Actinobacteria (actinomycetoma, 2.12%), deferobacteres (deironibacter, 1.30%), epsilon bacillaeota (0.77%) and Proteobacteria (Proteobacteria, 0.72%). The mice in the CRF1 model group with higher abundance are as follows: firmicutes (47.31%), bacteriodes (37.22%), Verrucomicrobia (9.12%), Actinobacteria (2.04%), deuteribacteria (1.67%), Proteobacteria (1.04%), episorberaotiota (0.33%). Compared with the blank control group, the CRF1 model group has the advantages that the intestinal tract microbial bacteroidetes is reduced, and the intestinal tract microbial bacteroides of firmicutes and verrucomicrobia is increased. The abundance of microorganisms of Bacteroides ubiquitina in intestinal tracts of mice in the Guangdong cordyceps sinensis treatment group (CK2, CK3, CRF2 and CRF3) is increased, and the abundance of microorganisms of firmicutes and verrucomicrobia is reduced.

At the genus level, as shown in fig. 11, the composition of intestinal abundance of placebo (CK1) mice was in order: turicibacter (zurich bacillus, 7.02%), Akkermansia (Akkermansia, 6.98%), Dubosiella (6.09%), Lactobacillus (Lactobacillus, 3.29%), Alistipes (corynebacterium, 2.27%), Clostridium (Clostridium, 1.95%), Bifidobacterium (Bifidobacterium, 1.79%), alloprevorella (bacteroides, 1.70%), etc.; wherein the abundance of the flora of unidentified genera is formed by the following sequence: murebacteriaceae (Bactericaceae, 31.94%), Lachnospiraceae (Lachnospiraceae, 14.56%), Prevotellaceae (Prevotella, 4.58%), Ruminococcaceae (Microbacteraceae, 2.13%), etc. In the intestines of mice in the CRF1 model group, microorganisms of Lactobacillus (2.30%), Bifidobacterium and unidentified genera of Bacillaceae (20.59%), Prevoteriaceae (2.59%) were all significantly reduced; microorganisms of the genus Exxomansia (9.12%), Bacteroides (5.54%) and the family Youngensis (10.22%) and the family Muostridiaceae (5.54%) of unidentified genera all rose significantly. The intestinal microorganisms of the general lactobacillus, bifidobacterium, murobacteriaceae and prevotellaceae in the cordyceps guangdongensis treatment groups (CK2, CK3, CRF2 and CRF3) and the positive control CRF4 mice all showed an increasing trend, and the microorganisms of the genera Exkermansia, Bacteroides, lachnospiraceae and verrucomicrobiaceae all showed a decreasing trend.

Distribution of nine, different flora in each sample

According to a visual circled graph of the corresponding relation between the Circos samples and species, the dominant flora in each sample is the family of the murine bacillaceae, but compared with other samples, the family of the murine bacillaceae and the family of the lactobacillus in the intestinal tracts of the mice of the CRF1 model group are obviously reduced, and the family of the verrucomicrobiaceae and the genus Exendin are obviously increased; after the cordyceps guangdongensis is perfused, the abundance of the murine bacteriaceae group and the lactobacillus group in the intestinal flora of the mice of the CRF group (CRF2 and CRF3) is obviously increased, and the abundance of the verrucomiciaceae group and the akkermansia group is obviously reduced (figure 12). The results show that the Guangdong cordyceps sinensis for gastric lavage can obviously improve the condition of imbalance of intestinal flora of mice with chronic renal failure and has obvious effect on treating diseases related to the intestinal flora.

Claims (8)

1. Application of Cordyceps guangdongensis in preparing product for preventing or treating intestinal dysbacteriosis or its related diseases is provided.

2. The use according to claim 1, characterized in that said use is represented by any one of the following aspects:

1) regulating the community composition of the intestinal flora;

2) regulating the diversity of intestinal flora;

3) regulating intestinal flora function;

4) regulating the abundance change of the intestinal flora.

3. The use according to claim 2, wherein said intestinal flora comprises Bacteroides (Bacteroides), Firmicutes (Firmicutes), Micromyces verrucosus (Verrucomicrobia), Actinomycetes (Actinobacterium).

4. Use according to claim 2, characterized in that said intestinal flora comprises the families of the species of the family of the Bacteribacteriaceae (Murebacteriaceae), Prevoteriaceae (Prevotella), Lachnospiraceae (Lachnospiraceae), Mycoplasmataceae (Ruminococcaceae).

5. The use according to claim 2, wherein the intestinal flora comprises the genera Lactobacillus (Lactobacillus), Bifidobacterium (Bifidobacterium), Exkermansia (Akkermansia), Rhizoctonia (Turciobacter), Bacteroides (Bacteroides).

6. The use according to claim 1, wherein the disease is chronic renal failure.

7. The use according to claim 6, characterized in that it is represented by any one of the following aspects:

1) improve the behavior of eating less and drinking more and reduce polyuria;

2) improving the symptoms of listlessness and the like;

3) improving the appearance of the kidney, wherein the appearance of the kidney comprises the color of the kidney, the luster of the appearance, whether the surface of the kidney is rough or withered or not and atrophy;

4) reduce serum creatinine and urea level.

8. A medicine for preventing and/or treating diseases related to intestinal dysbacteriosis is characterized by comprising cordyceps guangdongensis sporocarp and a pharmaceutically acceptable carrier.

Images